Gfast-OD Capsule PR contains Itopride 150 mg, a prokinetic agent indicated for the treatment of functional dyspepsia and gastrointestinal motility disorders. Itopride acts by enhancing acetylcholine release through dopamine D2 receptor antagonism and inhibiting acetylcholinesterase activity, thereby promoting gastric emptying and improving gastrointestinal motility. This pharmacological action helps alleviate symptoms such as bloating, nausea, early satiety, and abdominal discomfort associated with delayed gastric emptying. Gfast-OD Capsule PR is formulated as an orally disintegrating preparation, allowing for rapid dissolution and absorption, which is beneficial for patients with swallowing difficulties or those requiring prompt onset of action. The recommended dosage is one capsule (150 mg) taken orally, preferably before meals, or as directed by a healthcare professional. Itopride is generally well tolerated; however, adverse effects may include mild gastrointestinal disturbances, headache, and dizziness. Caution is advised in patients with a history of hypersensitivity to itopride or related compounds, and it should be used with care in individuals with hepatic or renal impairment. Gfast-OD Capsule PR should not be co-administered with drugs that prolong the QT interval or with other dopamine antagonists without medical supervision. Regular monitoring and adherence to prescribed dosage are essential to ensure therapeutic efficacy and safety.